Advances in Tuberculosis Diagnosis and Management: Insights from the Lungs

Avis Acres^*
*Correspondence: Avis Acres, Department of Pulmonary, University of Georgia, Athena, USA, Email:

Keywords

Cancer • Immune cells • Lung function

Introduction

TB has been a scourge on humanity for centuries, earning monikers like the "White Plague" and the "Captain of Death." It was not until the late 19^th and early 20^th centuries that significant advances in TB diagnosis and treatment were made. The development of the tuberculin skin test and the discovery of the first effective anti-TB drug, streptomycin, were pivotal moments in the fight against the disease. These historical milestones laid the foundation for the modern understanding of TB, but contemporary challenges persist, and new insights are essential. Imaging techniques have played a vital role in TB diagnosis. Chest X-rays have long been a staple in identifying pulmonary TB, helping clinicians visualize characteristic patterns of lung involvement. Recent advances in digital radiography and computer-aided diagnostics have improved the accuracy and speed of TB detection, reducing the time required for diagnosis.

Literature Review

Imaging techniques have played a vital role in TB diagnosis. Chest X-rays have long been a staple in identifying pulmonary TB, helping clinicians visualize characteristic patterns of lung involvement. Recent advances in digital radiography and computer-aided diagnostics have improved the accuracy and speed of TB detection, reducing the time required for diagnosis. High-resolution CT scans have revolutionized the visualization of TB's impact on the lungs. These scans provide detailed insights into the extent and location of pulmonary lesions, facilitating a more precise diagnosis and helping in monitoring treatment response. Moreover, CT scans are valuable in assessing the severity of the disease, including identifying complications such as cavities, bronchiectasis, and fibrotic changes [1].

The combination of PET with CT imaging has enabled the identification of metabolically active TB lesions within the lungs. This cutting-edge approach aids in distinguishing active TB from latent infections or other lung conditions. It is particularly useful in identifying regions with a high bacterial burden, assisting clinicians in targeted interventions and monitoring treatment outcomes. Molecular diagnostics have heralded a new era in TB diagnosis. NAATs, such as Polymerase Chain Reaction (PCR) and Loop-Mediated Isothermal Amplification (LAMP), target specific TB DNA or RNA sequences, enabling rapid and accurate identification of Mycobacterium tuberculosis. These tests have greatly reduced the time required for diagnosis and have proven indispensable in cases of drug-resistant TB. The GeneXpert system, utilizing real-time PCR, has gained prominence in TB diagnosis due to its simplicity and speed. It can simultaneously detect TB and rifampicin resistance in a matter of hours, making it an invaluable tool for timely initiation of treatment and prevention of transmission [2].

Discussion

NGS technologies have brought about a more comprehensive understanding of TB by enabling the sequencing of the entire TB genome. This has helped in identifying various strains, understanding their genetic diversity, and tracing transmission patterns. NGS has been crucial in unraveling the complex dynamics of drug resistance, as well as in vaccine development and epidemiological research. IGRAs, like the QuantiFERON-TB Gold test and T-SPOT.TB assay, have emerged as valuable tools for diagnosing latent TB infection. By measuring the release of interferon-gamma in response to TB-specific antigens, these tests provide insights into the immune response to TB. They are especially useful in high-burden settings and for individuals with a BCG vaccination history [3].

The study of cytokines and chemokines in TB infection has shed light on the immune response within the lungs. It has been found that imbalances in pro-inflammatory and anti-inflammatory cytokines can influence the progression and severity of TB. This insight has spurred research into potential immunomodulatory therapies to enhance the body's ability to combat the infection. Recent research has focused on identifying host-derived biomarkers in blood and sputum that can indicate active TB disease. Promising biomarkers include Lipoarabinomannan (LAM), C-Reactive Protein (CRP), and various microRNAs. These biomarkers hold potential for faster, non-invasive, and cost-effective TB diagnosis.

The genetic diversity of both Mycobacterium tuberculosis and the host plays a significant role in TB outcomes. Pharmacogenomic studies have identified genetic variants that influence an individual's response to anti-TB drugs. Understanding these genetic factors allows for personalized treatment regimens, minimizing the risk of adverse effects and treatment failure. Conventional TB treatment involves a combination of antibiotics over an extended period. Recent insights have led to the development of targeted therapies that address specific aspects of TB pathogenesis, such as drugs that inhibit mycobacterial cell wall synthesis or disrupt the host-pathogen interaction. These therapies offer the potential for shorter, more effective treatment regimens. Two recent breakthroughs in TB drug development are bedaquiline and delamanid. Bedaquiline was the first novel anti-TB drug approved by the FDA in over forty years. It targets the mycobacterial ATP synthase, providing an effective option for multidrug-resistant TB. Delamanid, another promising drug, inhibits mycolic acid synthesis, offering an alternative for drug-resistant TB patients. Host-directed therapies focus on enhancing the host's immune response to TB. This approach includes drugs that modulate host factors, such as interleukin-1 or tumor necrosis factor, to improve bacterial clearance. These therapies have the potential to complement antibiotic treatment and reduce treatment duration [4-6].

Conclusion

While BCG provides some protection against severe forms of TB, the development of new and more effective vaccines remains a priority. Subunit vaccines, viral-vectored vaccines, and whole-cell inactivated vaccines are among the candidates in various stages of clinical trials. Recent insights from vaccine research have illuminated the challenges and opportunities in developing a successful TB vaccine. Advancements in Artificial Intelligence (AI) and machine learning have transformed TB diagnosis and management. AI algorithms can analyze medical images, microbiological data, and clinical information to provide rapid and accurate diagnoses. They can also predict treatment outcomes and identify patients at risk of non-adherence, enhancing the overall quality of care. The battle against Tuberculosis (TB) has seen significant advances in diagnosis and management, offering hope in the ongoing fight against this ancient and formidable disease. The insights gained from the lungs, where TB primarily takes hold, have been central to these advancements, revolutionizing our understanding of the disease, and guiding the development of more effective strategies for prevention, diagnosis, and treatment.

The introduction of cutting-edge imaging technologies, such as high-resolution CT scans and PET-CT, has allowed clinicians to visualize the extent and activity of TB within the lungs with remarkable precision. This has led to earlier and more accurate diagnoses, essential for effective TB management. Molecular diagnostics, including Nucleic Acid Amplification Tests (NAATs) and the GeneXpert system, have greatly expedited the diagnostic process, facilitating timely treatment initiation and enabling healthcare providers to identify drug-resistant strains more efficiently.

The identification of biomarkers and the understanding of immunological responses in TB have opened new doors for diagnosis and treatment. Host-derived biomarkers, cytokines, and chemokines provide insights into the body's immune response, potentially allowing for non-invasive and cost-effective diagnostic tools. Meanwhile, pharmacogenomics and the development of targeted therapies promise personalized treatment regimens, increasing the chances of successful outcomes.

Acknowledgement

None.

Conflict of Interest

The authors declare that there is no conflict of interest associated with this manuscript.

References

1. Kwak, Jennifer J., Sree Harsha Tirumani, Annick D. Van den Abbeele and Phillip J. Koo, et al. "Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events." Radiographics 35 (2015): 424-437.

Google Scholar, Crossref, Indexed at

2. Disis, Mary L. "Mechanism of action of immunotherapy." Semin Oncol 41 (2014): S3-S13.

Google Scholar

3. Morse, Michael A., Paul J. Mosca, Timothy M. Clay and H. Kim Lyerly. "Dendritic cell maturation in active immunotherapy strategies." Expert Opin Biol Ther 2 (2002): 35-43.

Google Scholar, Crossref, Indexed at

4. Kokate, R. "A systematic overview of cancer immunotherapy: An emerging therapy." Pharm Pharmacol Int J 5 (2017): 31-35.

Google Scholar, Crossref, Indexed at

5. Hwang, William L., Luke RG Pike, Trevor J. Royce and Brandon A. Mahal, et al. "Safety of combining radiotherapy with immune-checkpoint inhibition." Nat Rev Clin Oncol 15 (2018): 477-494.

Google Scholar, Crossref, Indexed at

6. Braschi-Amirfarzan, Marta, Sree Harsha Tirumani, Frank Stephen Hodi and Mizuki Nishino. "Immune-checkpoint inhibitors in the era of precision medicine: What radiologists should know?" Korean J Radiol 18 (2017): 42-53.

Google Scholar, Crossref, Indexed at